Kim, J.E., Jang, J.S., Kim, J.W., Sung, Y.L., Cho, C.H., Lee, M.A., . . . Min, K.W. (2017). Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Supportive Care in Cancer, 25, 801–809.
The purpose was to evaluate the efficacy of a three-day aprepitant regimen to manage CINV during cycle one of moderately emetogenic chemotherapy.
Three-day regimen of aprepitant plus ondansetron and dexamethasone compared to three-day regimen of placebo plus ondansetron and dexamethasone.
PHASE OF CARE: Active anti-tumor treatment
Randomized, controlled trial, double-blind.
Measures of nausea and vomiting were not specifically described but aspects measured were vomiting during the overall phase (0-120 hours), use of rescue therapy during the overall phase, time to first vomiting event during the overall phase, vomiting during the acute (0–24 hours following initiation of chemotherapy) and delayed (25–120 hours following initiation of chemotherapy) phases.
Participants who received the three-day aprepitant regimen did not have statistically significant fewer episode of vomiting or use of rescue medications in the overall phase (0-120 hours after chemotherapy) as compared with those who received the placebo regimen.
The addition of aprepitant to a standard antiemetic regimen for moderately emetogenic chemotherapy did not result in significant improvement in CINV.
Measurement/methods not well described
For patients receiving moderately emetogenic chemotherapy, adding aprepitant to antiemetic therapy may not provide additional prevention of CINV.